M. Rother

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy et al. · Journal of Clinical Oncology · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +15

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

J.-Y. Douillard, Salvatore Siena, J Cassidy et al. · Annals of Oncology · 2014 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.

Salvatore Siena, Josep Tabernero, David Cunningham et al. · Journal of Clinical Oncology · 2010 · 30 citations

Medicine, Oncology, Pharmacology +17

Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer

Winson Y. Cheung, Gregory R. Pond, M. Rother et al. · Clinical Colorectal Cancer · 2008 · 27 citations

Medicine, Oncology, Surgery +11